Catalent Continues to Make Investments Into Expanding Its' Global Clinical Suppy Services Capacity and Offering

Somerset, NJ - June 30, 2011 - Catalent Pharma Solutions' Clinical Supply Services business has recently undertaken two global expansion initiatives that enhance the company's ability to provide unparalleled service to its customers in the controlled substance arena.

In the United States, Catalent's Philadelphia site has benefited from a recently completed 3,000 square feet cage expansion which can accommodate DEA Schedule III-V drugs, as well as other special security and storage needs.  The newly-approved DEA cage will provide 500 additional storage locations to existing capacity and provide additional storage, distribution, and return drug management capabilities.

"Our expansion is a direct result of the growing demand from our customers for DEA regulated and special security controlled logistics activities," said John Morrison, General Manager of Catalent's Philadelphia Clinical site.

Internationally, Catalent's facilities in Schorndorf, Germany are also undergoing expansion.  The expansion includes both additional controlled substance storage and increased warehousing space. Peter Brun, Director, Clinical Supply Services, notes that "the controlled drug storage expansion is planned to be completed by the end of June and will provide significant additional storage to enhance our global capabilities."

This enhanced global controlled substance capability, combined with Catalent's offerings in comparator sourcing, clinical packaging and labeling, manufacturing and blinding, and distribution and warehousing allows Catalent to better meet the needs of virtually any size clinical trial, with any drug, anywhere in the world - a capability unmatched by competitors in the industry.

About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 8,000 people at 24 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ.

more products. better treatments. reliably supplied.TM

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.